Clinical trials: Gastrointestinal Stromal Tumor
Small Size Gastrointestinal Stromal Tumors, GIST
RCT of EFTR Versus STER for GIST Treatment
Endoscopic resection has been increasing utilized as the treatment for small size gastrointestinal stromal tumors (GIST), of which the best resection method has not been identified.
- Trial name
- NCT07411118
- Testing
- Endoscopic full thickness resection (EFTR) / Exposed non-tunneling EFTR, Submucosal Tunneling Endoscopic Resection (STER) / Exposed tunneling EFTR
- Where
- 4 sites in China, Hong Kong and 2 more
- Volunteers
- 136 people
- Sponsor
- Chinese University of Hong Kong
Gastrointestinal Stromal Tumors
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
This study is an observational, multicenter, Real-word study to evaluate the safety and clinical efficacy of avapritinib in Chinese subjects with GIST.
- Trial name
- NCT05381753
- Testing
- Avapritinib, Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )
- Where
- China
- Volunteers
- 61 people
- Sponsor
- CStone Pharmaceuticals
Gastrointestinal Stromal Tumor (GIST)
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST.
- Trial name
- NCT06630234
- Testing
- DCC-3009
- Where
- 10 sites in United States
- Volunteers
- 120 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Gastrointestinal Stromal Tumors
A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)
This study consists of Dose escalation part and Expansion part. In Dose Escalation Part, the maximum tolerated dose of combination of pimitespib and imatinib in patients with gastrointestinal stromal tumors (GIST) who are judged…
- Trial name
- NCT05245968
- Testing
- Pimitespib, Imatinib, Sunitinib
- Where
- 14 sites in Australia, China and 3 more
- Volunteers
- 78 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Stomach Cancer, Gastro-Esophageal(GE) Junction Cancer
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
Our research of the biology of upper gastrointestinal cancers involves the study of tissue samples and cells from biopsies of persons with gastric or esophageal cancer or blood samples from upper gastrointestinal cancer patients…
- Conditions
- Stomach Cancer, Gastro-Esophageal(GE) Junction Cancer, Gastric (Stomach) Cancer, Esophageal Cancer
- Trial name
- NCT01048281
- Testing
- Blood draw, Tissue tumor biopsy
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Stanford University
GIST
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
This is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT…
- Trial name
- INSIGHT (NCT05734105)
- Testing
- Ripretinib, Sunitinib
- Where
- 70 sites in United States, Australia and 13 more
- Volunteers
- 54 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Gastrointenstinal Stromal Tumor (GIST), GIST - Gastrointestinal Stromal Tumor
A Comprehensive, Multinational GIST Registry
Patients diagnosed with a gastrointestinal stromal tumor (GIST), a rare type of tumor in the digestive tractparticipate in this scientific research study, known as a registry study, to help improve understanding and treatment of…
- Trial name
- reGISTTry (NCT07273045)
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- Universität Duisburg-Essen
GIST - Gastrointestinal Stromal Tumor
Ripretinib (QINLOCK®) According to Current SmPC
The goal of this prospective, observational study INTEREST is to collect real-world data on ripretinib treatment in a broad patient population in Germany. Ripretinib will be administered according to the current SmPC.
- Trial name
- INTEREST (NCT06619275)
- Testing
- Ripretinib
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- iOMEDICO AG
Gastrointestinal Stromal Tumor (GIST)
MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
The purpose of this study is to evaluate the effects, good and/or bad, of MEK162 and imatinib on the patient and on Gastrointestinal Stromal Tumor (GIST). Funding Source - FDA OOPD, Array/Pfizer
- Trial name
- NCT01991379
- Testing
- MEK162, Imatinib Mesylate (Gleevec®; STI571; NSC #716051), Blood draws
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastrointestinal Stromal Tumors, GIST
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
This is an open label, single arm, phase 2 trial investigating bezuclastinib plus sunitinib in patients with GIST who have previously progressed on sunitinib.
- Trial name
- NCT06208748
- Testing
- Bezuclastinib in combination with sunitinib
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
This study was a Phase Ib, multi-center, open-label study of TNO155 in combination with spartalizumab or ribociclib with a dose escalation part followed by a dose expansion part in adult subjects with advanced solid tumors.
- Conditions
- Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal SCC, Gastrointestinal Stromal Tumors
- Trial name
- NCT04000529
- Testing
- TNO155, Spartalizumab, Ribociclib
- Where
- 10 sites in United States, Australia and 7 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Gastrointestinal Stromal Tumors, Small-cell Lung Cancer
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.
- Conditions
- Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma
- Trial name
- NCT06805825
- Testing
- NN3201
- Where
- 5 sites in United States
- Volunteers
- 67 people
- Sponsor
- Novelty Nobility, Inc.
Hand-Foot Skin Reaction (HFSR)
ZINCLO-HAND: Zinc and Clobetasol for the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction
This study aims to evaluate whether a combination of oral zinc supplementation and transdermal clobetasol cream is effective in preventing and reducing the severity of hand-foot skin reaction (HFSR) induced by regorafenib…
- Trial name
- ZINCLO-HAND (NCT06856590)
- Testing
- Zinc Supplementation, Clobetasol Propionate 0.05% Cream
- Where
- 13 sites in Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Gazi University
Gastrointestinal Stromal Tumors
A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy
To assess anti-tumor activity of avelumab in combination with axitinib in patients with unresectable/metastatic GIST after progression on second or third line treatment (after failure on at least of imatinib and sunitinib) in…
- Trial name
- AXAGIST (NCT04258956)
- Testing
- Axitinib
- Where
- Poland
- Volunteers
- 58 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Advanced Gastrointestinal Stromal Tumors
Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
The treatment of advanced GIST patients is based on imatinib followed with sunitinib in case of resistance/intolerance. However, the median progression-free survival (PFS) on sunitinib is frequently short, and after failure with…
- Trial name
- CYCLIGIST (NCT01907607)
- Testing
- PD 0332991
- Where
- 9 sites in France
- Volunteers
- 29 people
- Sponsor
- Institut Bergonié
Gastrointestinal Stromal Tumor (GIST)
Resistance Profiling Using Functional Imaging and Next Generation Sequencing in Refractory Gastrointestinal Stomal Tumors (GIST)
Gastrointestinal stromal tumors (GIST) are the most common malignant sarcomas of the gastrointestinal tract. Inhibitors of the mutated driver proteins KIT and PDGFRA can temporarily control disseminated GIST disease but cannot…
- Trial name
- PATHFINDERS (NCT07109024)
- Testing
- Generation of a comprehensive and single-lesion resistance profile
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Universität Duisburg-Essen
Gastrointestinal Stromal Tumors
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
In this study, the investigators aim to investigate the efficacy and safety of 5 years of adjuvant imatinib treatment in patients with tumor rupture defined by Nishida classification or those with a tumor size 10cm or larger and…
- Trial name
- NCT05385549
- Testing
- Imatinib Mesylate
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Asan Medical Center
Submucosal Tumor, Gastrointestinal Stromal Tumor (GIST)
CEH-EUS for Differentiating GISTs and Leiomyomas: A Multicenter Prospective Self-Controlled Study
The investigators conduct a prospective, multicenter diagnostic trial primarily aimed at evaluating the value of contrast-enhanced harmonic endoscopic ultrasound (CEH-EUS) in differentiating gastrointestinal stromal tumors…
- Conditions
- Submucosal Tumor, Gastrointestinal Stromal Tumor (GIST), Leiomyoma
- Trial name
- NCT07106411
- Testing
- Endoscopic Ultrasound, Contrast-Enhanced Harmonic Endoscopic Ultrasound (CEH-EUS)
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Huazhong University of Science and Technology
Metastatic Gastrointestinal Stromal Tumors (GIST)
A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment
This study is a multicenter, prospective, randomized controlled Phase II clinical trial. The primary endpoint is to evaluate the efficacy and safety of regorafenib combined with envafolimab compared to physician's choice in…
- Trial name
- NCT06772233
- Testing
- regorafenib combined with envafolimab, Control Group
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University
Submucosal Tumor, Gastrointestinal Stromal Tumor (GIST)
Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis
This study develops a multimodal AI model using endoscopic ultrasound, white-light endoscopy, and clinical information to support the diagnosis of upper GI mesenchymal tumors and the risk stratification of gastric GISTs.
- Conditions
- Submucosal Tumor, Gastrointestinal Stromal Tumor (GIST), Leiomyoma, Schwannoma
- Trial name
- NCT07078136
- Testing
- Multimodal AI Model, Expert Endoscopist Assessment
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Huazhong University of Science and Technology